Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660810 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
A Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, sponsored by John Rieth.
- Active
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT06660810: Active Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, sponsored by John Rieth.
NCT06660810 is a Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue that is active but no longer recruiting, run by John Rieth. The registered enrollment target is 2 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06660810, a Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, is active but no longer recruiting, sponsored by John Rieth.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
Conditions Studied
Interventions
- PROCEDURE Surgery
- DRUG Talimogene Laherparepvec
- RADIATION Neoadjuvant Radiation
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2030-03-10 |
| Phase | Phase 2 |
What the registry record for NCT06660810 still lists
NCT06660810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Surgery is the first listed.
NCT06660810 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06660810 about?
NCT06660810 is a clinical study titled "Neoadjuvant Intralesional Injection of Talimogene Laherparepvec". The proposed study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
What is the current status of trial NCT06660810?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2025-03-03. Estimated completion is 2030-03-10.
What conditions does trial NCT06660810 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue.
What interventions are being tested in trial NCT06660810?
The interventions under investigation include: Surgery (PROCEDURE), Talimogene Laherparepvec (DRUG), Neoadjuvant Radiation (RADIATION).
Who is sponsoring clinical trial NCT06660810?
This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660810 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06660810's enrollment target sits among peer trials
2 55th of 55 the lowest of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI